Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer. Its lead candidate, ELVN-001, is a highly selective BCR-ABL inhibitor aimed at chronic myeloid leukemia, including heavily pretreated patients. A second program, ELVN-002, targets HER2-driven and HER2-mutant solid tumors. The company focuses on cancers where existing kinase drugs leave room for better selectivity or resistance coverage.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -25.3 | — |
| Q3 2025 | 0 | — | -20.1 | — |
| Q4 2025 | 0 | — | -29.7 | — |
| Q1 2026 | 0 | — | -23.6 | — |
| Q2 2026 | 0 | — | -32.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MGE Energy, Inc. (MGEE), DXP Enterprises, Inc. (DXPE), Ambarella, Inc. (AMBA), Skyward Specialty Insurance Group, Inc. (SKWD), CarGurus, Inc. (CARG), Aveanna Healthcare Holdings Inc. (AVAH)